Kuros Biosciences AG (KURN.SW) SIX

26.02

+0.3(+1.17%)

Updated at September 08 09:16AM

Currency In CHF

Kuros Biosciences AG

Address

Wagistrasse 25

Schlieren, 8952

Switzerland

Phone

41 44 733 4747

Sector

Healthcare

Industry

Biotechnology

Employees

122

First IPO Date

October 29, 2002

Key Executives

NameTitlePayYear Born
Mr. Christopher T. Fair B.B.A.Chief Executive Officer & Director724,6001970
Dr. Katherine Sage D.O., FAAOS, M.S.Senior Vice President of Medical & Clinical Affairs0N/A
Mr. Sjoerd MustersChief Operating Officer & GM of BV01980
Dr. Virginia JamiesonConsultant01953
Dr. Joost D. de Bruijn B.Sc. Ph.D., Ph.D.President of Innovation and Strategy & Executive Director01966
Ms. Laura RosaSenior Vice President of Global Human Resources0N/A
Dr. Philippe Saudan Ph.D.Chief Development Officer01967
Mr. Daniel GeigerChief Financial Officer01971
Mr. John GriffinChief Commercial Officer0N/A
Mr. G. Joseph RossSenior Vice President of Marketing & Business Development01968

Description

Kuros Biosciences AG, a biopharmaceutical company, engages in the commercialization and development of biopharmaceutical products for tissue repair and bone regeneration in the United States, the European Union, and internationally. It operates through Medical Devices, Pharmaceuticals, and Legacy Portfolio. The company's orthobiologics pipeline products include MagnetOs Granules and MagnetOs Putty in EU and US for the treatment of orthopedics, spinal, and dental problems. Its fibrin/PTH orthobiologics pipeline products comprise KUR-111, which has completed Phase 2b clinical trial for the treatment of tibial plateau fractures; and KUR-113, which completed Phase 2b clinical trial for the treatment of tibial shaft fractures, as well as is in the Phase II trial for the treatment of spinal interbody fusion. The company's sealants pipeline products include Neuroseal EU and US, synthetic tissue sealant for the prevention of cerebrospinal fluid leakage following cranial or spinal surgery. It has collaboration with Checkmate Pharmaceuticals LLC for the development of CYT003 for the treatment of oncology. The company is headquartered in Schlieren, Switzerland.